Immunotherapy-Chemo combo before surgery shows promise for advanced ovarian cancer

NCT ID NCT07673835

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether combining two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy before surgery can improve outcomes for people with advanced ovarian cancer. Participants receive 3-4 cycles of the combination, followed by surgery to remove visible tumors, then more chemo after surgery. The study aims to see if this approach extends the time before the cancer progresses. It enrolls 49 adults with stage III or IV ovarian, fallopian tube, or primary peritoneal cancer who are candidates for surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
iparomlimab and tuvonralimab (immunotherapy) plus platinum-based chemotherapy
What this could lead to
If successful, this combination could become a new standard neoadjuvant treatment for advanced ovarian cancer, potentially delaying disease progression.
What could go wrong
This is a small, early-phase trial with no control group, so results may not be definitive. Immunotherapy can cause immune-related side effects, and not all patients may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Obstetrics and Gynecology Hospital of Fudan University

    Shanghai, 201101, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.